Transforming clinical trial endpoint analysis: Clario implements over 30 AI solutions to deliver faster and accurate results

"When it comes to AI technology and clinical trials, it's not about one single solution," said Todd Rudo, Chief Medical Officer, Clario. "Clinical trials are complicated and unique to the medicine they are researching, so they require bespoke solutions. This is why Clario is developing AI solutions that tackle specific challenges across Cardiac Safety, eCOA, Imaging, Precision Motion and Respiratory for trial endpoint analysis. We currently have over 70 clinical trials enrolled in our various AI models, and our clients and their patients are already realizing the benefits: enhancements in our ability to collect a wide range of digital data types and subsequently analyze them faster and more accurately."

"When it comes to AI technology and clinical trials, it's not about one single solution," said Todd Rudo, Chief Medical Officer, Clario. "Clinical trials are complicated and unique to the medicine they are researching, so they require bespoke solutions. This is why Clario is developing AI solutions that tackle specific challenges across Cardiac Safety, eCOA, Imaging, Precision Motion and Respiratory for trial endpoint analysis. We currently have over 70 clinical trials enrolled in our various AI models, and our clients and their patients are already realizing the benefits: enhancements in our ability to collect a wide range of digital data types and subsequently analyze them faster and more accurately."

"AI is transforming clinical trials, but we have to be thoughtful in how we develop it for such a complex area. Clario's innovative approach is to work with our scientific experts to identify meaningful applications of artificial intelligence to improve our performance in data collection and analysis without compromising safety or quality assessments. AI is not a replacement for our scientists but an effective tool to assist them in their routine work. AI in clinical trials is clearly moving out of its infancy, and we are excited to be at the forefront of progress in this ever-evolving landscape," said Achim Schülke, EVP Chief Innovation Officer, Clario.

Since 2018, Clario has applied over 30 AI solutions that enhance scientists' data endpoint analyses by optimizing operations, integrating platforms, strengthening patient privacy and increasing quality and precision while reducing errors. The AI solutions across Clario's technology platform include:

Clario's innovation, development and implementation of multiple AI solutions for data endpoint analysis is transforming efficiency, accuracy and speed in clinical trials. For more information about Clario and its artificial intelligence solutions, please go to Clario.com.

About Clario

Clario is a leading healthcare research and technology company that generates the richest clinical evidence in the industry for our pharmaceutical, biotech and medical device partners. Across decentralized, hybrid and site-based trials, our deep scientific expertise, global scale and the broadest endpoint technology platform in the industry allows our partners to transform lives. Clario has the only technology platform that combines eCOA, cardiac safety, medical imaging, precision motion, and respiratory endpoints. Clario's global team of science, technology and operational experts have helped deliver more than 27,000 trials and contributed to over 500 FDA and EMEA new drug approvals involving more than seven million patients in over 100 countries. Our innovation has been transforming clinical trials for 50 years.

For more information, visit Clario.com or follow us on LinkedIn and Twitter. 

Clario Media Contact
Duncan Cantor
[email protected]

Logo - https://mma.prnewswire.com/media/1677749/Clario_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/transforming-clinical-trial-endpoint-analysis-clario-implements-over-30-ai-solutions-to-deliver-faster-and-accurate-results-301829987.html